IntraBio
IntraBio’s Levacetylleucine Succeeds in Phase 3 Trial for Ataxia-Telangiectasia, Plans FDA and EMA Approval
IntraBio; levacetylleucine; Ataxia-Telangiectasia; Phase 3; FDA approval; EMA; rare disease
FDA Approves IntraBio’s Aqneursa for Niemann-Pick Disease Type C, Marking Second Approval in a Week
IntraBio, Aqneursa, Niemann-Pick disease type C, FDA approval, rare neurodegenerative disease, levacetylleucine